Laurus Labs has completed the acquisition of balance 8,333 equity shares from the promoter group shareholders of Laurus Bio on November 20, 2023. With this acquisition the Company holds 87.59% shareholding (on fully diluted basis) in Laurus Bio.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
